Skip to main content
main-content

Prostate cancer

26-04-2018 | Oncology | News | Article

In other news: ESTRO 2018

This roundup of research presented at ESTRO 37 – the annual meeting of the European Society for Radiotherapy & Oncology, held in Barcelona, Spain – covers chemoradiotherapy in older non-small-cell lung cancer patients, predictors of mortality in radiotherapy-treated NSCLC patients, and ultra-hypofractionated radiotherapy for prostate cancer.

06-04-2018 | Oncology | News | Article

In other news

In this month’s roundup, we cover topics including laboratory eligibility criteria as a potential barrier to clinical participation and the impact of cognitive dysfunction on survival in patients with hematologic cancers. Read on to find out more.

29-03-2018 | Prostate cancer | News | Article

MRI-based approach noninferior to standard biopsy for prostate cancer detection

In men at clinical risk for prostate cancer, a strategy involving multiparametric magnetic resonance imaging risk assessment followed by targeted biopsy is noninferior, and may even be superior, to standard transrectal ultrasonography-guided biopsy, say the PRECISION researchers.

Source:

N Engl J Med 2018; Advance online publication

22-03-2018 | Prostate cancer | News | Article

News in brief

CHAARTED metastatic prostate cancer QoL findings favor docetaxel

In men with metastatic hormone-sensitive prostate cancer, the addition of docetaxel to androgen deprivation therapy leads to an initial dip in quality of life, with a subsequent benefit over time, show CHAARTED results published in the Journal of Clinical Oncology.

21-03-2018 | Oncology | News | Article

EU mortality rates predicted to decline for many tumor types

Mortality rates associated with most of the major cancer sites are expected to decline in the European Union in 2018, research indicates.

Source:

Ann Oncol 2018; Advance online publication

19-03-2018 | Prostate cancer | News | Article

Regulatory update

EMA issues warning for radium-223 dichloride in prostate cancer

The EMA has recommended against the concomitant use of radium-223 dichloride in men who are receiving abiraterone acetate plus prednisone/prednisolone for prostate cancer.

image credits